IP Library Granted Patent US 8,143,218
Granted Patent B2
US 8,143,218 · App. 11/284,430 · Granted Mar 27, 2012

Treatment of skin, and wound repair, with thymosin beta 4

Assignee: Regenerx Biopharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,218
App. No.
11/284,430
Granted
Mar 27, 2012
Kind
B2
Abstract

Compositions and methods for treatment of skin utilizing thymosin β4.

Claims (24)

1. A composition for topical administration to skin, comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3; human transforming growth factor β1, and a pharmaceutically acceptable topical vehicle.

2. A composition for topical administration to skin comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3; human vascular endothelial growth factor and a pharmaceutically acceptable topical vehicle.

3. The composition according to claim 2 , wherein said vehicle is an oil in water, or water in oil emulsion.

4. A method for improving damage to the skin, the method comprising:

applying topically to said damaged skin a composition comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3; and a pharmaceutically acceptable topical vehicle.

5. A method for improving damage to the skin, the method comprising:

applying topically a composition comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3, human transforming growth factor β1, and a pharmaceutically acceptable topical vehicle.

6. A method for improving damage to the skin, the method comprising:

applying topically a composition comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3, human vascular endothelial growth factor, and a pharmaceutically acceptable topical vehicle.

7. The method according to claim 6 , wherein said skin damaged by irradiation or contains scar tissue.

8. The method according to claim 7 , wherein said cosmetically acceptable vehicle is an oil in water, or water in oil emulsion.

9. A composition for topical treatment of skin, comprising a thymosin beta 4 of SEQ ID NO:3 and a vehicle acceptable for topical administration, further comprising transforming growth factor beta, vascular endothelial growth factor, or both.

10. The composition of claim 9 , further comprising transforming growth factor beta.

11. The composition of claim 10 , wherein said transforming growth factor beta is transforming growth factor beta 1.

12. The composition of claim 9 , further comprising vascular endothelial growth factor.

13. The composition of claim 9 , wherein said vehicle is a lotion, cream, suspension, dispersion or oil.

14. A method of treating damaged skin tissue in a subject comprising topically administering the composition of claim 9 , to said subject.

15. A method of regenerating or revitalizing skin tissue in a subject comprising topically administering the composition of claim 9 , to said subject.

16. The method of claim 14 , wherein said vehicle is a lotion, cream, suspension, dispersion or oil.

17. The composition of claim 1 wherein said skin is in need of repair.

18. The composition of claim 2 wherein said skin is in need of repair.

19. The method of claim 4 wherein said skin is in need of repair.

20. The method of claim 5 wherein said skin is in need of repair.

21. The method of claim 6 wherein said skin is in need of repair.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 8, 2010
From: GOLDSTEIN, ALLAN L.; KLEINMAN, HYNDA K.; MALINDA, KATHERINE; SOSNE, GABRIEL
To: REGENERX BIOPHARMACEUTICALS, INC.; UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH
Reel/Frame 024492/0808 →
CHANGE OF NAME Recorded Jun 8, 2010
From: ALPHA 1 BIOMEDICALS
To: REGENERX BIOPHARMACEUTICALS, INC.
Reel/Frame 024492/0830 →
Continuity (4)
Continuation 09772445 · Jan 29, 2001
Continuation PCTUS9917282 · Jul 29, 1999
Provisional Application 60094690 · Jul 30, 1998
Related Publication 20070009469A1 · Jan 11, 2007